Lung Cancer News and Research

RSS

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).

3D cell culture system may be a valuable tool for assessing drug efficacy on tumor growth

Fibroblasts build and maintain the extracellular matrix, or physical scaffolding for cells, in the connective tissues within the body.

29 Mar 2023

Macrophages likely to be a potential target for ER+ breast cancer

Most immunotherapies that aim to increase T cell activity are ineffective in treating estrogen receptor-positive (ER+) breast cancer. A new study of invasive ER+ breast cancers led by researchers at the University of Pittsburgh School of Medicine implies that targeting a different type of immune cell called macrophages may be a more effective approach.

From University of Pittsburgh 20 Mar 2023

Immune landscape in invasive ER+ breast cancers reveals a macrophage-driven microenvironment

Most immunotherapies, which aim to boost T cell activity, work poorly in treating estrogen receptor-positive (ER+) breast cancer.

20 Mar 2023

Neoadjuvant dual immunotherapy and chemotherapy improve outcomes in patients with resectable NSCLC

In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).

20 Mar 2023

Potential approach to improve solid tumor T cell therapy

Researchers at the Perelman School of Medicine at the University of Pennsylvania have been working on a preclinical study that focuses on a new strategy that uses a “one-two punch” to assist T cells in attacking solid tumors.

17 Mar 2023

Using PET and electron microscopy to generate 3D maps of mitochondrial networks in lung tumors

Scientists have long known that mitochondria, the "powerhouses" of cells, play a crucial role in the metabolism and energy production of cancer cells.

16 Mar 2023

New center offers electron microscope services to the scientific community

The Joint Electron Microscopy Center at ALBA (JEMCA) was established through the collaboration of various research agencies to open a new center within the ALBA Synchrotron building that provides electron microscope assistance to the scientific community.

27 Feb 2023

Strata Oncology publishes study validating integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the publication of a new peer-reviewed study validating the clinical utility of the company's proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit, Immunotherapy Response Score (IRS).

8 Feb 2023

Study sheds light on why lung tumors do not respond well to immunotherapy

Immunotherapy -; drug treatment that stimulates the immune system to attack tumors -; works well against some types of cancer, but it has shown mixed success against lung cancer.

6 Feb 2023

A high-throughput drug discovery assay for the endoplasmic reticulum aminopeptidase 1

The January 2023 issue of SLAS Discovery contains a collection of four full-length articles and one technical brief covering cancer research, high-throughput screening (HTS) assay development and other drug discovery exploration.

31 Jan 2023

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Jan 2023

Persistent tumor mutation load may help predict outcome of novel immunotherapies

Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy.

27 Jan 2023

New gene helps drive the development of the common lung cancer type

At the NYU Langone Health’s Perlmutter Cancer Center, a team headed by scientists has determined a gene that forces the development of the second most common type of lung carcinoma.

From New York University (NYU) 11 Jan 2023

NIH funds research on mRNA vaccines to stop cancer development

The National Cancer Institute at the National Institutes of Health has awarded a multidisciplinary team of Weill Cornell Medicine researchers a five-year $5.7 million grant to support a center dedicated to creating messenger RNA (mRNA) vaccines to prevent the development of cancer in at-risk groups.

15 Nov 2022

Lung cancer treatment with protein insights

Scientists studying the mechanics of lung cancer’s early stages have discovered a new potential treatment that could also aid in the early detection of the disease.

10 Nov 2022

Encouraging breakthroughs in eliminating therapy-resistant cancer cells

The human immune system is notably adept at evading tumor cells, which construct physical barriers, adopt masks, and restrain the immune system with molecular ploys.

14 Sep 2022

Researchers analyze the significance of cellular interactions for lung cancer

A new Cleveland Clinic study has uncovered vital information about the cellular interaction of tumor cells and normal tissue, leading to a better understanding of how therapeutic resistance evolves.

5 Jul 2022

Researchers analyze the involvement of immune cells in lung cancer survival

Lung cancer affects approximately 48,500 persons in the United Kingdom every year. New treatments are urgently needed because only around 20% of patients live 5 years after diagnosis, and it is the leading cause of cancer death.

1 Jun 2022

Researchers created ultrasound-guided microbubbles to enhance immunotherapy performance

The University of Texas MD Anderson Cancer Center scientists have created an ultrasound-guided cancer immunotherapy approach that promotes systemic antitumor immunity and increases immune checkpoint blockade therapeutic potential. Nature Nanotechnology published the results of the pioneering study.